Neurosurgical lesioning for Tourette syndrome - Authors' reply
- PMID: 36931795
- DOI: 10.1016/S1474-4422(23)00079-0
Neurosurgical lesioning for Tourette syndrome - Authors' reply
Conflict of interest statement
KAJ receives fellowship funding from the National Science Foundation and travel grant awards from the International Congress of Parkinson's Disease and Movement Disorders. AG has received grant funding from the National Institutes of Health (NIH; R01NS096008) and the National Science Foundation (PECASE 1553482); support from the Tourette Association of America; device donations from Medtronic under an NIH contract; and is a board member of the Brain Computer Interfaces Society. KDF receives research support and fellowship support from Medtronic and Boston Scientific and research support from Functional Neuromodulation. CRB has received support from the NIH (UH3 NS119844) and has been a consultant for NeuraModix. MSO is a medical advisor for the Parkinson's Foundation; has received research grants from the NIH, Parkinson's Foundation, the Michael J Fox Foundation, the Parkinson Alliance, Smallwood Foundation, the Bachmann-Strauss Foundation, the Tourette Syndrome Association, and the University of Florida Foundation; has received support for research from the NIH (R01 NR014852, R01NS096008, UH3NS119844, and U01NS119562); and is principal investigator of the NIH R25NS108939 Training Grant. All other authors declare no competing interests.
Comment on
-
Tourette syndrome: clinical features, pathophysiology, and treatment.Lancet Neurol. 2023 Feb;22(2):147-158. doi: 10.1016/S1474-4422(22)00303-9. Epub 2022 Oct 28. Lancet Neurol. 2023. PMID: 36354027 Free PMC article. Review.
-
Neurosurgical lesioning for Tourette syndrome.Lancet Neurol. 2023 Apr;22(4):292. doi: 10.1016/S1474-4422(23)00078-9. Lancet Neurol. 2023. PMID: 36931796 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical